Insulet Corporation
Rank #51HypergrowthPODD · Nasdaq · Healthcare
Insulet Corporation (PODD) — Rank #51 by gross profitability (GP/assets 0.61) · ROE 17.4% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001145197 · all metrics point-in-time as of the filing date.
About
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Show moreShow less
The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- insulet.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-18 | 2024-12-31filed 2025-02-21 | 2023-12-31filed 2024-02-23 | 2022-12-31filed 2023-02-24 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 90.4 | 80.8 | 72.8 | 63.2 |
| Stock-based compensation | 62.7 | 69.3 | 48.3 | 40.9 |
| Change in receivables | — | — | 99.4 | 12.9 |
| Change in inventory | 10.6 | 32.4 | 53.6 | 49.1 |
| Change in payables | 49.2 | 2.2 | (11.0) | (2.4) |
| Operating cash flow | 569.3 | 430.3 | 145.7 | 119.0 |
| Investing | ||||
| Capital expenditures | 191.6 | 124.9 | 75.6 | 122.9 |
| Investing cash flow | (222.7) | (146.2) | (119.4) | (191.1) |
| Financing | ||||
| Debt issued | — | — | — | — |
| Debt repaid | — | — | — | — |
| Share repurchases | 59.6 | — | — | — |
| Financing cash flow | (595.3) | (28.1) | (13.6) | (40.3) |
| Summary | ||||
| Free cash flow | 377.7 | 305.4 | 70.1 | (3.9) |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?